Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06237153 · ClinicalTrials.gov registry record · Phase 2
Randomized Placebo Controlled Study of Triamcinolone Acetonide Extended Release Injection for Thumb (CMC) Osteoarthritis
A Phase 2 study of Carpometacarpal (CMC) Osteoarthritis, sponsored by Marie Badalamente.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06237153 is a Phase 2 study of Carpometacarpal (CMC) Osteoarthritis that is actively recruiting participants, run by Marie Badalamente. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06237153, a Phase 2 study of Carpometacarpal (CMC) Osteoarthritis, is actively recruiting participants, sponsored by Marie Badalamente.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to investigate if a timed release steroid injection may be beneficial in treating carpometacarpal (CMC) joint (thumb) osteoarthritis. The main questions to be answered are: 1. does the steroid injection substantially reduce pain in the thumb 2. does the steroid injection help to increase thumb function Participants will be asked to undergo a thumb CMC joint injection and to attend follow up visits to assess pain and thumb function.
Conditions Studied
Interventions
- DRUG Triamcinolone Acetonide extended release suspension
Study Locations (1)
New York
- Stony Brook Orthopaedics - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06237153
The ClinicalTrials.gov registry entry for NCT06237153 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marie Badalamente, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carpometacarpal (CMC) Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which Triamcinolone Acetonide extended release suspension is the first listed.
NCT06237153 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06237153 about?
NCT06237153 is a clinical study titled "Randomized Placebo Controlled Study of Triamcinolone Acetonide Extended Release Injection for Thumb (CMC) Osteoarthritis". The goal of this study is to investigate if a timed release steroid injection may be beneficial in treating carpometacarpal (CMC) joint (thumb) osteoarthritis. The main questions to be answered are: 1. does the steroid injection substantially reduce pain in the thumb 2. does the steroid injection h...
What is the current status of trial NCT06237153?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-11-21. Estimated completion is 2025-12-31.
What conditions does trial NCT06237153 study?
This clinical trial studies the following conditions: Carpometacarpal (CMC) Osteoarthritis.
What interventions are being tested in trial NCT06237153?
The interventions under investigation include: Triamcinolone Acetonide extended release suspension (DRUG).
Who is sponsoring clinical trial NCT06237153?
This trial is sponsored by Marie Badalamente, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06237153 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.